Media stories about AVEO Pharmaceuticals (NASDAQ:AVEO) have trended somewhat positive on Thursday, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AVEO Pharmaceuticals earned a news impact score of 0.08 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.4961911420623 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- AVEO Pharmaceuticals, Inc. (AVEO) Receives Average Recommendation of “Hold” from Brokerages (americanbankingnews.com)
- Featured Volatile Stock – AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) – Alpha Beta Stock (alphabetastock.com)
- Here’s Why AVEO Oncology Rose as Much as 13.7% Today – Motley Fool (fool.com)
- Hot Mover of the Day: AVEO Pharmaceuticals Inc (NASDAQ: AVEO) – Alpha Beta Stock (alphabetastock.com)
- Here's Why AVEO Oncology Rose as Much as 13.7% Today (finance.yahoo.com)
Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) opened at $2.82 on Thursday. The stock has a market capitalization of $333.63, a P/E ratio of -3.97 and a beta of 1.14. The company has a debt-to-equity ratio of -0.32, a current ratio of 2.33 and a quick ratio of 2.33. AVEO Pharmaceuticals has a 52 week low of $0.50 and a 52 week high of $4.24.
AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.03. equities analysts expect that AVEO Pharmaceuticals will post -0.66 EPS for the current year.
AVEO has been the subject of several recent analyst reports. B. Riley reissued a “buy” rating and set a $5.00 price objective on shares of AVEO Pharmaceuticals in a report on Tuesday. Zacks Investment Research raised AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. BidaskClub lowered AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 9th. initiated coverage on AVEO Pharmaceuticals in a report on Wednesday, November 15th. They set a “buy” rating and a $5.00 price objective for the company. Finally, Seaport Global Securities reissued a “buy” rating on shares of AVEO Pharmaceuticals in a report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $4.05.
ILLEGAL ACTIVITY WARNING: This article was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://ledgergazette.com/2018/01/18/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-aveo-pharmaceuticals-aveo-share-price.html.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.